$3.52
-0.02-0.56%
Last update: Nov 10, 7:51 PM
Aquestive Therapeutics Inc
AQSTNASDAQ
Aquestive Therapeutics fell 36.6% from $5.58 to $3.54, behind the S&P 500's +10.0%. Its worst day was Jan 9 (−37.0%), and its low came Jan 30 at $2.95.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Aquestive Therapeutics closed at its highest level of the year, 18.6% above where the year started.
+3.8% · S&P 500 −0.3%
Story events cover the past 12 months · Times ET
Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time Receives confirmation from FDA that Agency’s review of Anaphylm NDA application is
−37.0%, the year's worst day · S&P 500 +0.7%
Aquestive Therapeutics closed at its lowest level of the year, 47.1% below where the year started.
−6.6% · S&P 500 −0.3%
EPS of $-0.15 missed the $-0.12 estimate on $13.0M revenue (est. $13.3M); FY revenue guidance of $46.0M–$50.0M against the $47.4M consensus.
−2.5% · S&P 500 −0.6%
EPS of $-0.07 beat the $-0.13 estimate on $14.4M revenue (est. $10.9M); FY revenue guidance of $46.0M–$50.0M against the $48.1M consensus.
+14.5% · S&P 500 +0.8%
EPS of $-0.18 missed the $-0.12 estimate on $13.8M revenue (est. $11.7M); FY revenue guidance of $46.0M–$50.0M against the $50.8M consensus.
−4.1% · S&P 500 +0.3%
EPS of $-0.13 beat the $-0.13 estimate on $7.6M revenue (est. $11.0M); FY revenue guidance of $46.0M–$50.0M against the $50.9M consensus.
−2.1% · S&P 500 +1.7%
Where it ended: a close of $3.54 on Nov 9, 2026. Up next: Q4 2026 earnings on Mar 3, 2027 (EPS est. $-0.10, revenue est. $13.2M).
Nothing in the past 12 months.
All AQST analyst actionsNothing in the past 12 months.
All AQST dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for AQST and SPY from Benzinga historical bars. Not investment advice.
